Login to Your Account



Clinic Roundup


Tuesday, June 18, 2013

• Array Biopharma Inc., of Boulder, Colo., said interim results from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory multiple myeloma (MM) who are refractory or intolerant to Velcade (bortezomib) were reported at the European Hematology Association meeting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription